Completed suicides in 47 psychiatric hospitals in germany results from the AGATE-study

Pharmacopsychiatry

Volumn 44, Issue 7, 2011, Pages 324-330

  Neuner, T ^a   Hubner Liebermann B ^a   Haen, E ^a   Hausner, H ^a   Felber, W ^b   Wittmann, M ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

AGATE study; psychiatric inpatients; psychopharmacotherapy; suicide

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BIPERIDEN; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; DOXEPIN; FIRST GENERATION ANTIPSYCHOTIC; HALOPERIDOL; LORAZEPAM; MELPERONE; MIRTAZAPINE; NEUROLEPTIC AGENT; NORADRENERGIC AND SPECIFIC SEROTONERGIC ANTIDEPRESSANT; OLANZAPINE; RISPERIDONE; SECOND GENERATION ANTIPSYCHOTIC; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; UNCLASSIFIED DRUG; HYPNOTIC SEDATIVE AGENT; PSYCHOTROPIC AGENT;

ADULT; ALCOHOLISM; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG POTENCY; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HOSPITAL; MIXED ANXIETY AND DEPRESSION; MOOD DISORDER; PANIC; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SUICIDE; FACTUAL DATABASE; HOSPITAL PATIENT; MENTAL DISORDERS; MIDDLE AGED; MOOD DISORDERS; PSYCHOLOGY; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DATABASES, FACTUAL; FEMALE; GERMANY; HOSPITALS, PSYCHIATRIC; HUMANS; HYPNOTICS AND SEDATIVES; INPATIENTS; MALE; MENTAL DISORDERS; MIDDLE AGED; MOOD DISORDERS; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SOCIOECONOMIC FACTORS; SUICIDE;

EID: 80855127943     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0031-1284428     Document Type: Article

References (56)

1. Bowers L, Banda T, Nijman H. Suicide inside. A systematic review of inpatient suicides. J Nerv Ment Dis: 2010; 198 315 328
2. Cassells C, Paterson B, Dowding D et al. Long- and short-term risk factors in the prediction of inpatient suicides: review of literature. Crisis: 2005; 26 53 63 (Pubitemid 41020128)
3. Deisenhammer E A, DeCol C, Honeder M et al. Inpatient suicide in psychiatric hospitals. Acta Psychiatr Scand: 2000; 102 290 294
4. Dong JY S, Ho T P, Kan C K. A case-control study of 92 cases of in-patient suicides. J Affect Disord: 2005; 87 91 99 (Pubitemid 40828207)
5. Neuner T, Schmid R, Wolfersdorf M et al. Predicting inpatient suicides and suicide attempts by clinical routine data? Gen Hosp Psychiat: 2008; 30 324 330 (Pubitemid 351862315)
6. Sharma V, Persad E, Kueneman K. A closer look at inpatient suicide. J Affect Disord: 1998; 47 123 129 (Pubitemid 28066767)
7. Spiel H, Hbner-Liebermann B, Cording C. Suicidal behaviour of psychiatric inpatients. Acta Psychiatr Scand: 2002; 106 134 138
8. Steblaj A, Tavcar R, Dernovsek M Z. Predictors of suicide in psychiatric hospital. Acta Psychiatr Scand: 1999; 100 383 388 (Pubitemid 29493645)
9. FDA Public Health Advisory. Worsening depression and suicidality in patients being treated with antidepressants March 22: 2004; Available at http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvi-sories/ ucm161696.htm
10. Hammad T A, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry: 2006; 63 332 339 (Pubitemid 43345358)
11. Whittington C J, Kendall T, Fonagy P et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet: 2004; 363 1341 1345 (Pubitemid 38529872)
12. FDA Public Health Advisory. Suicidality in children and adolescents being treated with antidepressant medications Juni 30: 2005; Available at http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053169. htm
13. FDA Public Health Advisory Antidepressant use in children, adolescents, and adults May 2,: 2007; Available at http://www.fda.gov/Drugs/DrugSafety/ InformationbyDrugClass/ucm096273.htm
14. Fergusson D, Doucette S, Glass K C et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ: 2005; 330 396
15. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo-controlled, randomised controlled trials submitted to the MHRAs safety review. BMJ: 2005; 330 385
16. Reeves R R, Ladner E. Antidepressant-induced suicidality: an update. CNS Neuroscience and Therapeutics: 2010; 16 227 234
17. Mller H J. Antidepressants: controversies about their efficacy in depression, their effect on suicidality and their place in a complex psychiatric treatment approach. World J Biol Psychiatry: 2009; 10 180 195
18. Teicher M H, Glod C A, Cole J O. Antidepressant drugs and the emergence of suicidal tendencies. Drug Saf: 1993; 8 186 212 (Pubitemid 23123065)
19. Rihmer Z. Suicide risk in mood disorders. Curr Opin Psychiatry: 2007; 20 17 22 (Pubitemid 44901071)
20. Akiskal H S, Benazzi F, Perugi G et al. Agitated unipolar depression reconceptualized as depressive mixed state: implications for the antidepressant-suicide controversy. J Affect Dis: 2005; 85 245 258 (Pubitemid 40386508)
21. Mihanovi M, Restek-Petrovi B, Bodor D et al. Suicidality and side effects of antidepressants and antipsychotics. Psychiatria Danubia: 2010; 22 79 84
22. Siris S G. Suicide and schizophrenia. J Psychopharmacol: 2001; 15 127 135 (Pubitemid 32619590)
23. Wolfersdorf M. Suicide among psychiatric inpatients. In Hawton K, van Heeringen K. eds. The international handbook of suicide and attempted suicide. Chichester John Wiley & Sons Ltd: 2000; 457 466
24. Haen E. Qualittssicherung in der Psychopharmakotherapie. Neurotransmitter: 2004; 7/8 37 43
25. Gaertner I, Gilot C, Heidrich P et al. A case control study on psychopharmacotherapy before suicide committed by 61 psychiatric inpatients. Pharmacopsychiatry: 2002; 35 37 43 (Pubitemid 34293231)
26. Proulx F, Lesage A D, Grunberg F. One hundred inpatient suicides. Br J Psychiatry: 1997; 171 247 250
27. Taiminen T J. Effect of psychopharmacotherapy on suicide risk in psychiatric inpatients. Acta Psychiatr Scand: 1993; 87 45 47 (Pubitemid 23024865)
28. De Hert M, Correll C U, Cohen D. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophr Res: 2010; 117 68 74
29. Haukka J, Tiihonen J, Hrknen T et al. Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia. Pharmacoepidemiol Drug Saf: 2008; 17 686 696
30. Tiihonen J, Wahlbeck K, Lnnqvist J et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ: 2006; 333 224
31. Tiihonen J, Lnnqvist J, Wahlbeck K et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11study). Lancet: 2009; 374 620 627
32. Hawton K, Sutton L, Haw C et al. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry: 2005; 187 9 20 (Pubitemid 41002508)
33. Hawton K, van Heeringen K. Suicide. Lancet: 2009; 373 1372 1381
34. Pompili M, Lester D, Grispini A et al. Completed suicide in schizophrenia: evidence from a case-control study. Psychiatry Res: 2009; 167 251 257
35. Aguilar E J, Siris S G. Do antipsychotic drugs influence suicidal behavior in schizophrenia? Psychopharmacol Bull: 2007; 40 128 142
36. Altamura A C, Bassetti R, Bignotti S et al. Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study. Schizophr Res: 2003; 60 47 55 (Pubitemid 36015787)
37. Altamura A C, Bobo W V, Meltzer H Y. Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. Int Clin Psychopharmacol: 2007; 22 49 267
38. Montout C, Casadebaig F, Lagnaoui R et al. Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients. Schizophr Res: 2002; 57 147 156 (Pubitemid 35240016)
39. Drake R E, Gates C, Cotton P G et al. Suicide among schizophrenics. Who is at risk? J Nerv Ment Dis: 1984; 172 613 617
40. Pompili M, Ruberto A, Kotzalidis G A et al. Awareness of illness and suicide in schizophrenia: an overview. Bull Menninger Clin: 2004; 68 297 318
41. Shrivastava A, Johnston M E, Shah N et al. Persistent suicide risk in clinically improbe schizophrenia patients: challenge of the suicidal dimension. Neuropsychiatr Dis Treat: 2010; 6 633 638
42. Palmer D D, Henter I D, Wyatt R J. Do antipsychotic medications decrease the risk of suicide in patients with schizophrenia? J Clin Psychiatry: 1999; 60 S2 100 103 111116 (Pubitemid 29101971)
43. Meltzer H Y, Alphs L, Green A I et al. Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (InterSePT). Arch Gen Psychiatry: 2003; 60 82 91 (Pubitemid 36070868)
44. Baldessarini R J, Tondo L, Hennen J. Lithium treatment and suicide risk in major affective disorders: update and new findings. J Clin Psychiatry: 2003; 64 S44 S52
45. Cipriani A, Pretty H, Hawton K et al. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry: 2005; 162 1805 1819 (Pubitemid 41428610)
46. Lauterbach E, Felber W, Mller-Oerlinghausen B et al. Adjunctive lithium treatment in the prevention of suicidal behaviour in depressive disorders: a randomised, placebo-controlled, 1-year trial. Acta Psychiatr Scand: 2008; 118 469 479
47. Mller-Oerlinghausen B, Lewitzka U. Lithium reduces pathological aggression and suicidality: a mini-review. Neuropsychobiology: 2010; 62 43 49
48. Rubino A, Roskell N, Tennis P et al. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ: 2006; 334 242
49. Mines D, Hill D, Yu H et al. Prevalance of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram. Pharmacoepidemiol Drug Saf: 2005; 14 367 372 (Pubitemid 40895543)
50. Salem B A, Karam E G. Duloxetine and suicide attempts: a possible relation. Clin Pract Epidemiol Ment Health: 2008; 4 18
51. Acharya N, Rosen A S, Polzer J P et al. Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder. J Clin Psychopharmacol: 2006; 26 587 594 (Pubitemid 44772735)
52. Courtet P. Suicidality: risk factors and the effects of antidepressants. The example of parallel reduction of suicidality and other depressive symptoms during treatment with the SNRI, milnacipran. Neuropsychiatr Dis Treat: 2010; 6 3 8
53. Dubicka B, Hadley S, Roberts C. Suicidal behaviour in youths with depression treated with new-generation antidepressants. Br J Psychiatry: 2005; 189 393 398
54. Kasper S, Montgomery S A, Mller H J et al. Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder. World J Biol Psychiatry: 2010; 11 36 44
55. Stone M, Laughren T, Jones M L et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ: 2009; 339 b2880
56. Wittmann M, Hausner H, Hajak G et al. Suizidalitt und Psychopharmakotherapie im hheren Lebensalter eine Auswertung der AGATE. Suicidality and psychopharmacological therapy in old age results from the AGATE. Suizidprophylaxe: 2009; 36 82 88